1. Evaluation and testing of polymethylmetacrylic (PMMA) bone cements with admixed Amphotericin B.
- Author
-
Frank FA, Krampitz B, Steiner J, Strathausen R, Morgenstern M, Clauss M, and Kühn KD
- Subjects
- Humans, Male, Female, Materials Testing methods, Antifungal Agents, Aged, Middle Aged, Candidiasis drug therapy, Bone Cements chemistry, Polymethyl Methacrylate chemistry, Amphotericin B, Prosthesis-Related Infections drug therapy
- Abstract
Background: Amphotericin is admixed to Polymethylmethacrylic (PMMA) spacers for fungal periprosthetic joint infections (PJI) during two-stage exchanges. We aimed to analyse the mechanical properties of PMMA cement with admixed Amphotericin B., Materials and Methods: We tested Amphotericin in PMMA cement mechanically, its elution properties in vitro and present two cases of fungal PJI treated with Amphotericin B powder in Copal cement in vivo., Results: Sterile Amphotericin B is not available as a pure substance but only as powder for infusions. PMMA mixed with such pharmaceutical Amphotericin B formulations colored the cement orange. Compression strength was slightly decreased, bending and impact strength significantly decreased whereas bending modulus was increased. Drug elution was high within the first 24 h and decreased over time until day 5. Amphotericin B in combination with Copal was successfully used in two cases with Candida ssp., Infections: No negative side effects, especially no nephrotoxic effects, were observed. Sterile Amphotericin B powder for preparing an infusion solution contains only small amounts of pure drug. In vivo polymicrobial Candida-infections with bacterial co-infection were successfully treated using the combination of Copal cements with added Amphotericin B without systemic nephrotoxic impact., Conclusions: The addition of Amphotericin B to PMMA cement affects the cement's properties in vitro whereas in vivo the combination with Copal is clinically successful in treating complex cases of fungal PJI., Level of Evidence: Level IV., Competing Interests: Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Written informed consent has been obtained from the patients to publish this paper. Competing interests: F.F., M.M. and J.S. declare they have no competing interests. M.C. received a grant from Heraeus Medical unrelated to this research. B.K., R.S. and K.-D.K. are employed by Heraeus Medical., (© 2025. The Author(s).)
- Published
- 2025
- Full Text
- View/download PDF